|
Mercado cerrado -
Nasdaq
22:00:00 06/02/2026
|
Variación 5 días
|
Varia. 1 de enero.
|
|
43,09 USD
|
+1,20 %
|
 |
-1,89 %
|
+4,46 %
|
|
14/01 |
Kiniksa Pharmaceuticals International, plc Appoints Management Team, Effective January 10, 2026
| | |
12/01 |
Kiniksa Pharmaceuticals International : J.P. Morgan 2026 Presentation
| | |
12/01 |
Kiniksa Pharmaceuticals provides corporate update
| | |
12/01 |
Kiniksa Pharmaceuticals Provides Corporate Update
| | |
07/01 |
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
| | |
17/12 |
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $500,715, According to a Recent SEC Filing
| | |
17/12 |
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $835,555, According to a Recent SEC Filing
| | |
17/11 |
Kiniksa Pharmaceuticals International : Presentation
| | |
12/11 |
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
| | |
28/10/25 |
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
| | |
28/10/25 |
Kiniksa Pharmaceuticals International : Corporate Presentation – October 2025
| | |
28/10/25 |
Kiniksa Pharmaceuticals International, plc Raises Net Sales Guidance for the Full Year 2025
| | |
28/10/25 |
Kiniksa Pharmaceuticals Swings to Q3 Net Income, Revenue Increases
| | |
28/10/25 |
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.32
| | |
28/10/25 |
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International, plc Reports Q3 Revenue $180.9M, vs. FactSet Est of $167.4M
| | |
28/10/25 |
Kiniksa Pharma raises ARCALYST's 2025 sales forecast
| | |
28/10/25 |
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
| | |
23/10/25 |
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
| | |
22/10/25 |
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $10,023,532, According to a Recent SEC Filing
| | |
22/10/25 |
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $1,962,781, According to a Recent SEC Filing
| | |
17/10/25 |
Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation
| | |
17/10/25 |
Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387
| | |
17/10/25 |
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
| | |
17/09/25 |
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $597,976, According to a Recent SEC Filing
| | |
08/09/25 |
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,506,278, According to a Recent SEC Filing
| |
No hay resultados para esta búsqueda Selecciona tu edición Toda la información financiera adaptada al ámbito nacional.
MarketScreener is also available in this country: United States.
Switch edition
Seguir con la edición actual
| 
